Retention of Neutralizing response against SARS-CoV-2 Omicron variant in Sputnik V vaccinated individuals
Country: Italy
Key facts
Read the article
Sputnik V demonstrates strong protection against Omicron variant, more than 2 times higher virus neutralizing activity than Pfizer vaccine against Omicron
Neutralization antibody titer against Omicron
Source: «Retention of Neutralizing response against SARS-CoV-2 Omicron variant in Sputnik V vaccinated individuals»
The study demonstrates that Sputnik V neutralizes Omicron variant inducing robust antibody response associated with high levels of protection
Each group of sera samples was divided into 7 parts according to RBD-specific IgG (BAU/ml) quartiles (0-25%, 25-50%, 50-75%, 75-100%, 0-50%, 25-75% and 50-100%)
*NtAb – neutralization antibody level
Sputnik Light booster after Sputnik V vaccination induces robust neutralizing antibody response to B.1.1.529 (Omicron) SARS-CoV-2 variant
Country: Russia
Nationwide effectiveness of five SARS-CoV-2 vaccines in Hungary - The HUN-VE study
Country: Hungary
COVID-19 in the Republic of Belarus: pandemic features and the interim safety and efficacy assessment of the Gam-COVID-Vac vaccine
Country: Belarus
Safety and preliminary efficacy of the Gam-COVID-Vac vaccine and outcomes of SARS-CoV-2 infection in Russian patients with genitourinary malignancies
Prevalence of COVID-19 vaccines (Sputnik V, AZD-1222, and Covaxin) side effects among healthcare workers in Birjand city, Iran
Country: Iran
Side effects and Immunogenicity following administration of the Sputnik V COVID-19 vaccine in health care workers in Iran
An open, non-randomised, phase 1/2 trial on the safety, tolerability, and immunogenicity of single-dose vaccine “Sputnik Light” for prevention of coronavirus infection in healthy adults
Evaluation of a COVID-19 Vaccine Campaign and SARS-CoV-2 Infection and Mortality Among Adults Aged 60 Years And Older in a Middle-Income Country
Country: Argentina
Boosting of the SARS-CoV-2-specific immune response after vaccination with single-dose Sputnik Light vaccine
Safety and Effectiveness of COVID-19 SPUTNIK V Vaccine in Dialysis Patients
Sputnik V Protection from COVID-19 of HIV-Infected Individuals Under Art
One-shot immunization with Sputnik Light (the first component of Sputnik V vaccine) is effective against SARS-CoV-2 Delta variant: efficacy data on the use of the vaccine in civil circulation in Moscow
SARS-CoV-2 vaccines breakthrough infection hospitalizations after one dose in Libya: cohort study
Country: Libya
SARS-CoV-2 Antibody Response Following SPUTNIK V Vaccination in Healthcare Workers From a Hospital in Argentina: Preliminary Results
Prospective Cohort Study of the Kinetics of Specific Antibodies to SARS-CoV-2 Infection and to Four SARS-CoV-2 Vaccines Available in Serbia, and Vaccine Effectiveness: A 3-Month Interim Report
Country: Serbia
Effectiveness of the first component of Gam-COVID-Vac (Sputnik V) on reduction of SARS-CoV-2 confirmed infections, hospitalisations and mortality in patients aged 60-79: a retrospective cohort study in Argentina
Temporal Increase in Neutralization Potency of SARS-CoV-2 Antibodies and Reduced Viral Variant Escape after Sputnik V Vaccination
Sputnik V vaccine elicits seroconversion and neutralizing capacity to SARS-CoV-2 after a single dose
Immune responses following the first dose of the Sputnik V (Gam-COVID-Vac)
Country: Sri Lanka
Neutralizing Activity of Sera from Sputnik V-Vaccinated People against Variants of Concern (VOC: B.1.1.7, B.1.351, P.1, B.1.617.2, B.1.617.3) and Moscow Endemic SARS-CoV-2 Variants
ROCCA observational study: Early results on safety of Sputnik V vaccine (Gam-COVID-Vac) in the Republic of San Marino using active surveillance
Country: San Marino
Active monitoring of early safety of Sputnik V vaccine in Buenos Aires, Argentina
Estimating SARS-CoV-2 Spike Antibody Levels Among Sputnik V First Dose Vaccinated People in Pakistan: Formulation of Anti-COVID-19 National Mass Vaccination Strategy
Country: Pakistan
Evaluation of the neutralizing antibodies response to Sputnik V vaccine in a cohort in the city of Córdoba and evaluation of the neutralizing properties of the natural and vaccine antibodies against the Manaus variant
Sputnik V elicits a high immune response even with a single dose
Sputnik V COVID-19 vaccine candidate appears safe and effective
Safety and efficacy of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine: an interim analysis of a randomised controlled phase 3 trial in Russia
Safety and immunogenicity of an rAd26 and rAd5 vector-based heterologous prime-boost COVID-19 vaccine in two formulations: two open, non-randomised phase 1/2 studies from Russia
Message has been successfully sent!
